All Tech Innovators

John W. Mellors

View all technologies

Fully Human Fabs Binding to the CD94/NKG2A Heterodimer

05650

Fully human antibodies block CD94/NKG2A, restoring NK/T cell activity against cancer and HIV, with strong specificity.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Infectious Disease
Oncology
Therapeutic Indications: HIV
Lung Cancer - Non-Small Cell
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Yae Jin Kim
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-03-23
Collections: Women's & Reproductive Health

Fluid Removal Algorithm for Acute Kidney Injury

05831

A standardized, data-driven fluid removal tool for ICU dialysis in AKI, aiming to reduce hypotension and complications.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - scFV
Therapeutic Areas: Oncology
Therapeutic Indications: Solid tumor
Leukemia
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
John W. Mellors
Zehua Sun
Date Submitted: 2021-10-06

Novel Llama Nanobody to Treat HIV-1

06827

Humanized llama nanobody 4E2 neutralizes diverse HIV-1 variants, mimicking CD4 with low immunogenicity, promising therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Immunology
Infectious Disease
Therapeutic Indications: HIV
Tags: Drug Discovery - Target
Life Science
Lead Inventor: Wei Li
Department: Med-Medicine
All Tech Innovators: Zhiwei Feng
Margaret Grace Hines
Wei Li
Date Submitted: 2024-07-26
Collections: Women's & Reproductive Health
Healthcare AI

uPAR-Targeting Human Antibody for Treating Cancer and Fibrotic Diseases

06240

uPAR-targeting human VH antibodies offer potent, versatile cancer and fibrotic-disease therapy with VH-Fc formats.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Hepatology
Oncology
Therapeutic Indications: Cirrhosis
Melanoma
Prostate cancer / adenocarcinoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Xiaojie Chu
Dimiter Stanchev Dimitrov
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-12-06
Collections: Cardiometabolic
Women's & Reproductive Health

Next-Generation Long-Lasting Soluble CD4-D1 Domains as HIV Entry Inhibitors

06603

Engineered soluble CD4-D1 variant offers long-lasting HIV entry inhibition with enhanced stability, MHC II avoidance, and broad neutralization.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Bispecific
Therapeutic Areas: Infectious Disease
Therapeutic Indications: HIV
Lead Inventor: Wei Li
Department: Med-Medicine
All Tech Innovators: Xiaojie Chu
Jana Lynn Jacobs
Wei Li
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2024-01-08
Collections: Women's & Reproductive Health

Fully Human Fab and VH Antibody Binding to SIRPa

06871

Fully human antibodies block SIRPα–CD47, restore macrophage phagocytosis, boosting cancer immunotherapy potential.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Lead Inventor: Seungmin Shin
Department: Med-Medicine
All Tech Innovators: Dimiter Stanchev Dimitrov
Wei Li
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2024-09-09

Fully Human Fab and VH Antibody Binding to PLA2G7

06870

Fully human antibodies block PLA2G7 to reduce inflammation, with potential anti-aging and cancer therapies.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Bispecific
Therapeutic Areas: Oncology
Cardiovascular
Therapeutic Indications: Stroke
Atherosclerotic disease
Tags: Aging
Lead Inventor: Seungmin Shin
Department: Med-Medicine
All Tech Innovators: Dimiter Stanchev Dimitrov
Wei Li
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2024-09-09
Collections: Cardiometabolic

Identification of Fully Human Antibodies

05676

Fully human PSCA-targeting antibodies enable potent ADCC and ADCs against PSCA+ cancers, including prostate tumors.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Renal cell carcinoma (RCC)
Pancreatic adenocarcinoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-04-21

Human Monoclonal Antibodies against SARS-CoV-2

05259

Neutralizing human monoclonal antibodies target SARS-CoV-2 spike RBD, blocking entry or directing infected-cell killing.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Covid-19
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Chuan Chen
Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2020-02-26

Fully Human Antibodies Targeting Membrane Proximal Region in Human CEACAM5

05469

Fully human CEACAM5-targeting antibody binds membrane-proximal region with nanomolar affinity, high specificity, and potential NEPC therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2020-08-06

Fully Human Anti-Mesothelin Engineered Antibody VH Domains

05170

Fully human VH-domain CAR-T targets mesothelin tumors; smaller, potentially less immunogenic, improved penetration and cryptic-epitope access.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - scFV
Therapeutic Areas: Oncology
Therapeutic Indications: Pancreatic adenocarcinoma
Ovarian cancer
Mesothelioma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
John W. Mellors
Zehua Sun
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-11-15
Collections: Women's & Reproductive Health

PSMA with Multiple Single-Chain and Domain Binders Treats Prostate Cancer

05717

PSMA-targeting VH-domain antibodies enable potent ADCs, ADCC, or CAR-T for prostate cancer with improved penetration.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-06-09

Human Antibody Domains and Fragments to CD276

04890

Fully human antibody domains and fragments target CD276 (B7-H3) to enhance solid tumor immunotherapy and tumor penetration.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Bispecific
Therapeutic Areas: Oncology
Therapeutic Indications: Solid tumor
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Wei Li
John W. Mellors
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-02-11

Fully Human FAbs to IGF-1 and IGF-2

04929

Fully human IGF-1/IGF-2–binding Fabs block IGF signaling to curb cancer cell growth, offering novel therapeutics.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Ductal carcinoma (Breast cancer)
Colorectal cancer (CRC)
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-03-24
Collections: Women's & Reproductive Health

Integrated Proviral Sequencing Assay (IPSA)

04724

IPSA rapidly amplifies and sequences rare viral integration sites with host flanking DNA, enabling scalable HIV, HBV, and herpes research.

Technology Type: Diagnostic/Assay
Technology Subtype: In vitro Diagnostic
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Hepatitis B
Lead Inventor: Kevin Joseph
Department: Med-Medicine
All Tech Innovators: Kevin Joseph
John W. Mellors
Date Submitted: 2018-08-30

Human Antibody Domains and Fragments to CD276

06094

engineered fully human single-domain antibodies and Fabs targeting CD276 (B7-H3) for potent, broadly applicable cancer immunotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Melanoma
Prostate cancer / adenocarcinoma
Glioblastoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Dontcho V. Jelev
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-07-06

Antibody Domains that bind to Neutrophil Elastase (NE) polypeptides

05643

Antibody domains targeting neutrophil elastase inhibit its activity, offering cancer and inflammatory disease therapy with ADC potential.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Ductal carcinoma (Breast cancer)
Lung cancer - other
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Xiaojie Chu
Dimiter Stanchev Dimitrov
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-03-17
Collections: Women's & Reproductive Health

Fully Human Fabs to CD22 (bCAT1)

04874

Fully human anti-CD22 D7 binders enable CAR-T and ADCs for B-cell cancers, targeting proximal epitopes for enhanced efficacy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Therapeutic Indications: Lymphoma
Leukemia
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-01-27